


**Supplementary materials**

**Figure S1. Time course of single-lesion severity in IC-treated mice with measurable KS-like lesions or no lesions.**

BKV/Tat transgenic mice bearing initial lesions or no lesions were treated with IC at 0, 4, 8 days as described in Methods (4 mice). The Figure shows the single lesion severity over time of the IC-treated mice already presented in Figure 2.



**Table S1. Early-stage versus late-stage anti-Tat Ab treated lesions progressing to a score  $\geq 3$  over the monitoring course.**

	n/N	%
Early-stage anti-Tat Ab treatment	1/7	14.29
Late-stage anti-Tat Ab treatment	6/8	75.00
Early-stage control-Ab treatment	4/10	40.00
Late-stage control-Ab treatment	3/5	60.00

IC-treated (day 0, 4, 8) mice with early-stage (score  $\leq 0.5$ ) or late-stage (score  $\geq 1$ ) KS-like lesions were inoculated with anti-Tat Abs or control Abs (day 4, 8, 12). Mice were monitored twice/week and lesion severity scored up to week 12. The Table shows the number and percentage of mice progressed to a score  $\geq 3$  over the monitoring course.